http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3634472-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e704801555fbd6eaa01235f3c803e76f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 |
| filingDate | 2018-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1a7310d09380f5488bad63702a8106b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce7a60da62cb357f1d6d1b0fa1a047d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c13a5d32c053d50a1793c38996c693ee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a1022ad67f4af14c806a6d335609685 |
| publicationDate | 2020-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3634472-A1 |
| titleOfInvention | Compositions and methods for treating pulmonary hypertension |
| abstract | Methods treating pulmonary hypertension, including pulmonary arterial hypertension, are provided, and include administering a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof. Adminstration of the polypeptide antagonist reduces pulmonary artery acceleration time, reduces an amount of right ventricular hypertrophy, reduces right ventricular wall thickness, reduces an amount of pulmonary vessel wall thickness, reduces an amount of plexiform lesions in a lung of the subject, reduces an amount of collagen deposition in a pulmonary blood vessel, reduces an amount of collagen deposition in a pulmonary blood vessel media or adventitia, and/or reduces an amount of right ventricular fibrosis. Methods of reducing pulmonary vessel wall thickness are also provided and include the administration of the polypeptide antagonist of a Na/K ATPase/Src receptor complex. |
| priorityDate | 2017-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 249.